Long-term remission of hepatitis-associated aplastic anemia possibly due to immunosuppressive therapy after liver transplantation

Kiichiro Kanamitsu, Kousuke Chayama, Kana Washio, Ryuichi Yoshida, Yuzo Umeda, Takahito Yagi, Akira Shimada

Research output: Contribution to journalArticle

Abstract

Hepatitis-associated aplastic anemia (HAAA) is an acquired bone marrow failure syndrome that develops after seronegative fulminant hepatitis. Abnormal cytotoxic T-cell activation with cytokine release is a possible pathophysiology. We present the case of a 16-month-old Japanese male who developed HAAA following living- donor liver transplantation for fulminant hepatitis. His aplastic anemia was successfully treated with immunosuppressive therapy. He had been administered tacrolimus for prophylaxis against hepatic allograft rejection. Ten years after the HAAA onset, the patient's bone marrow was found to be slightly hypoplastic. Tacrolimus may be effective in controlling abnormal immune reactions that can cause recurrent impaired hematopoiesis.

Original languageEnglish
Pages (from-to)515-518
Number of pages4
JournalActa Medica Okayama
Volume72
Issue number5
Publication statusPublished - Jan 1 2018

    Fingerprint

Keywords

  • Abnormal immune reaction
  • Hepatitis-associated aplastic anemia
  • Immunosuppressive therapy
  • Impaired hematopoiesis
  • Liver transplantation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this